Leap Therapeutics, Inc. Common Stock
Symbol: LPTX (NASDAQ)
0.49
▼ (-5.66%) -0.030
Company Description:
Leap Therapeutics Inc is a biopharmaceutical company developing novel biomarker-targeted antibody therapies designed to treat patients with cancer by inhibiting fundamental tumor-promoting pathways, targeting cancer-specific cell surface molecules, and harnessing the immune system to attack cancer cells. The company's key clinical-stage drug candidate is sirexatamab (DKN-01), which targets Dickkopf-related protein 1 (DKK1) and is being studied in a clinical trial in patients with colorectal cancer. In addition, it also has a preclinical program to develop a proprietary monoclonal antibody, called FL-501 which works by inhibiting the GDF-15 protein.
Key Stats
- Today's Open: $0.495
- Today's High: $0.495
- Today's Low: $0.486
- Today's Volume: 24.12K
- Yesterday Close: $0.5226
- Yesterday High: $0.5749
- Yesterday Low: $0.4943
- Yesterday Volume: 1.89M
- Last Min Volume: 14
- Last Min High: $0.493
- Last Min Low: $0.493
- Last Min VWAP: $0.493
Company Profile
- Name: Leap Therapeutics, Inc. Common Stock
- Website: https://www.leaptx.com
- Listed Date: 2014-07-31
- Location: CAMBRIDGE, MA
- Market Status: Active
- CIK Number: 0001509745
- SIC Code: 2834
- SIC description: PHARMACEUTICAL PREPARATIONS
- Market Cap: $29.61M
- Round Lot: 100
- Outstanding Shares: 56.65M
- Asset Type: CS
RECENT FILINGS FOR LPTX
| Filing Date | Filing Type | Format |
|---|---|---|
| 2025-10-20 | 8-K | View |
| 2025-10-16 | SCHEDULE 13D | View |
| 2025-10-09 | 8-K | View |
| 2025-10-06 | 8-K | View |
| 2025-09-11 | 8-K | View |
| 2025-08-14 | SCHEDULE 13G/A | View |
| 2025-08-14 | 8-K | View |
| 2025-08-14 | 10-Q | View |
| 2025-07-01 | 4 | View |
| 2025-07-01 | 4 | View |
| 2025-07-01 | 4 | View |
| 2025-06-23 | 8-K | View |
| 2025-05-13 | 8-K | View |
| 2025-05-13 | 10-Q | View |
| 2025-04-28 | ARS | View |
| 2025-04-28 | DEFA14A | View |
| 2025-04-28 | DEF 14A | View |
| 2025-04-01 | 4 | View |
| 2025-04-01 | 4 | View |
| 2025-04-01 | 4 | View |
Latest News on LPTX